Eupraxia Pharmaceuticals Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing locally delivered, extended-release therapies designed to improve how medicines act within targeted tissues. The company’s work centers on its proprietary DiffuSphere delivery platform, which is used to reformulate existing and novel drugs for controlled release in the right place over an extended period. Eupraxia Pharmaceuticals Inc. is advancing product candidates for conditions with significant unmet medical need, including inflammatory and pain-related disorders, eosinophilic esophagitis, and other localized therapeutic areas. Its current business is built around drug delivery technology, clinical development, and intellectual property, positioning the company within the biotechnology and specialty pharmaceuticals sectors. Headquartered in Victoria, British Columbia, Canada, Eupraxia Pharmaceuticals Inc. focuses on improving local treatment performance while limiting broader systemic exposure.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. James A. Helliwell FRCPC, M.D.
- Employees
- 49
- Headquarters
- Victoria, BC, Canada
- Website
- www.eupraxiapharma.com